Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Incyte Corporation

  Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Incyte

Business Wire

NEW YORK -- March 6, 2013

Robbins Geller Rudman & Dowd LLP (“Robbins Geller”)
( today announced that a class action has
been commenced on behalf of an institutional investor in the United States
District Court for the District of Delaware on behalf of purchasers of Incyte
Corporation (“Incyte”) (NASDAQ:INCY) common stock during the period between
April 26, 2012 and August 1, 2012 (the “Class Period”).

If you wish to serve as lead plaintiff, you must move the Court no later than
60 days from today. If you wish to discuss this action or have any questions
concerning this notice or your rights or interests, please contact plaintiff’s
counsel, Samuel H. Rudman or David A. Rosenfeld of Robbins Geller at
800/449-4900 or 619/231-1058, or via e-mail at If you are a
member of this class, you can view a copy of the complaint as filed or join
this class action online at Any member
of the putative class may move the Court to serve as lead plaintiff through
counsel of their choice, or may choose to do nothing and remain an absent
class member.

The complaint charges Incyte and certain of its officers and directors with
violations of the Securities Exchange Act of 1934. Incyte is a pharmaceutical
company that has obtained U.S. Food and Drug Administration (“FDA”) approval
for distribution and sale in the United States of its drug Jakafi
(ruxolitinib), which is indicated for the treatment of patients with
intermediate or high-risk myelofibrosis.

The complaint alleges that during the Class Period, defendants made materially
false and misleading statements concerning Incyte’s business and prospects,
including about the demand for its myelofibrosis drug, Jakafi. Based on
defendants’ reports of strong sales demand for Jakafi and their positive
statements supporting the Company’s increased sales growth guidance for fiscal
2012, Incyte stock traded at inflated prices throughout the Class Period,
reaching over $26 per share by July 10, 2012.

According to the complaint, however, Incyte’s reported fourth quarter 2011 and
first quarter 2012 sales had been artificially inflated due to a large number
of extremely sick, advanced-stage myelofibrosis patients being prescribed the
drug initially upon FDA approval in November 2011, during the fourth quarter
of 2011 and first quarter of 2012 – patients who had been too sick to
participate in the clinical trials. Critically, many of these extremely sick,
more advanced patients were discontinuing use of Jakafi during the second
quarter of 2012, which was significantly diminishing Jakafi’s second quarter
2012 sales growth. And despite knowing that these more sickly patients had
been precluded from participating in the FDA drug trials, defendants
repeatedly assured investors they could rely on the drug dropout rates
achieved during the clinical trials to determine the then-current dropout

On August 2, 2012, Incyte announced the Company’s second quarter 2012
financial results for the period ended June 30, 2012, and disclosed that
Jakafi sales growth had been much softer during the second quarter of 2012
than investors and certain stock analysts had been led to expect. Defendants
also disclosed for the first time that many of the new patients prescribed
Jakafi during the fourth quarter of 2011 and first quarter of 2012 “were [so]
very advanced ... they would not have been eligible for the Phase III trial in
which life expectancy had to be at least six months.” Defendants also conceded
that while prescriptions to these patients had increased fourth quarter 2011
and first quarter 2012 sales revenues, those were not revenues that would
continue for the three years on average that defendants had claimed during the
Class Period the pre-approval clinical data had suggested patients would
remain on Jakafi, because, as defendants were forced to disclose during
Incyte’s August 2, 2012 conference call, “early on we had people discontinue
because they died.” In response to these disclosures, the price of Incyte
stock fell precipitously from its August 1, 2012 close of $24.92 per share to
close at $19.57 per share on August 2, 2012, a 22% decline, on extremely high

Plaintiff seeks to recover damages on behalf of all purchasers of Incyte
common stock during the Class Period (the “Class”). The plaintiff is
represented by Robbins Geller, which has expertise in prosecuting investor
class actions and extensive experience in actions involving financial fraud.

Robbins Geller represents U.S. and international institutional investors in
contingency-based securities and corporate litigation. With nearly 200 lawyers
in nine offices, the firm represents hundreds of public and multi-employer
pension funds with combined assets under management in excess of $2 trillion.
The firm has obtained many of the largest recoveries and has been ranked
number one in the number of shareholder class action recoveries in MSCI’s Top
SCAS 50 every year since 2003. According to Cornerstone Research, the firm’s
recoveries have averaged 35% above the median for all firms over the past
seven years (2005-2011). Please visit for more


Robbins Geller Rudman & Dowd LLP
Samuel H. Rudman, 800-449-4900
David A. Rosenfeld
Press spacebar to pause and continue. Press esc to stop.